Clinical Trials Browser

Phase NA × OTHER × aumolertinib × Clear all

NCT06102928 2023-10-26

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Phase NA Recruiting

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

NCT04944069 2021-06-29

ATTRACT

Phase NA Unknown

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis